A novel series of CCR5 antagonists has been identified, utilizing leads from high-throughput screening which were further modified based on insights from competitor molecules. Lead optimization was pursued by balancing opposing trends of metabolic stability and potency. Selective and potent analogs with good pharmacokinetic properties were successfully developed. (C) 2009 Elsevier Ltd. All rights reserved.
A novel series of CCR5 antagonists has been identified, utilizing leads from high-throughput screening which were further modified based on insights from competitor molecules. Lead optimization was pursued by balancing opposing trends of metabolic stability and potency. Selective and potent analogs with good pharmacokinetic properties were successfully developed. (C) 2009 Elsevier Ltd. All rights reserved.
Evaluation of a 4-aminopiperidine replacement in several series of CCR5 antagonists
作者:Rémy C. Lemoine、Ann C. Petersen、Lina Setti、Lijing Chen、Jutta Wanner、Andreas Jekle、Gabrielle Heilek、André deRosier、Changhua Ji、David M. Rotstein
DOI:10.1016/j.bmcl.2010.02.004
日期:2010.3
The bicyclic 5-amino-3-azabicyclo[3.3.0]octanes were shown to be effective replacements for the conformationally restricted 4-aminopiperidine ring found in several series of CCR5 antagonists. (C) 2010 Elsevier Ltd. All rights reserved.